Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471576 | 0.82 | LTA4H (0.44) | LTA4HLMNAKDM4ERAB9AALDH1A1 | |
| SCHEMBL343795 | 0.81 | F7 (0.49) | KMT2AL3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL2206232 | 0.74 | CES2 (0.40) | CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2203971 | 0.74 | KEAP1 (0.44) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29902994 | 0.74 | CES2 (0.40) | CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL23216806 | 0.72 | JAK1 (0.44) | LTA4HKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL343289 | 0.72 | LTA4H (0.50) | LTA4HKMT2AMEN1LMNACDK2 | |
| SCHEMBL31145901 | 0.72 | THRB (0.42) | KMT2AMEN1KDM4EHSD17B10RAB9A | |
| SCHEMBL344086 | 0.71 | LTA4H (0.58) | LTA4HKMT2AMEN1LMNAHTT | |
| SCHEMBL10252235 | 0.70 | L3MBTL1 (0.42) | LTA4HKMT2AMEN1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1798223-A2 | Aryl sulfonamides | ChemoCentryx Inc (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6939885-B2 | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | LTA4H 196/4885KMT2A 2760/4885MEN1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.